

Assessment of Quantitative D-dimer levels in Egyptian Patients with Budd-Chiari syndrome

Thesis

*Submitted for Partial Fulfillment of Master Degree in
Tropical Medicine*

By

Mohamed Ahmed Bahgat

M.B.B.CH

Faculty of Medicine - Ain Shams University

Supervised by

Professor/ Mohamed Amin Sakr

Professor of Tropical Medicine

Faculty of Medicine- Ain Shams University

Professor/ Manal Fawzy Ghozlan

Professor of clinical pathology

Faculty of Medicine- Ain Shams University

Doctor/ Runia Fouad EL-Folly

Assistant Professor of Tropical Medicine

Faculty of Medicine- Ain Shams University


Faculty of Medicine- Ain shams university

2014

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قُلْ إِنِّي كَلِمَةٌ نَدُّهَا

صدق الله العظيم
سورة طه آية (١١٤)



*First and foremost thanks to **ALLAH**,
the most merciful*

*I wish to express my deep appreciation and sincere gratitude to **Prof. Mohammad Amin Sakr**, Professor of Tropical Medicine, Ain Shams University, for his close supervision, valuable instructions, continuous help, patience and guidance. He has generously devoted much of his time and effort for planning and supervision of this study. It was a great honor to me to work under his supervision.*

*No words can fulfill the feeling of thanks I carry to **Prof. Manal Fawzy Ghozlan** Professor of Clinical Pathology and Hematology, Ain Shams University, for her continuous meticulous support and supervision.*

*I wish to express my sincere gratitude to **Ass. Prof. Runia Fouad El Folly**, Assistant Professor of Tropical Medicine, Ain Shams University, for her continuous help, cooperation and encouragement.*

Last, but not least, I must express my deepest thanks to all members of BCSG who helped me in this work and patients who allowed me to produce this study.

Mohamed Bahgat

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iii
List of Abbreviations	v
Protocol	--
Introduction	1
Aim of the Work	4
Review of literature	
▪ Hepatic Vascular Physioanatomic Spotlights	5
▪ Budd-Chiari Syndrome (BCS)	15
▪ Hemostasis	47
▪ Fibrinolysis	60
▪ D-Dimer	63
Patients and Methods	70
Results	79
Discussion	97
Summary	110
Conclusions	113
Recommendations	114
References	115
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Tables of Review of Literature		
Table (I):	Approximate prevalence of major risk factors in patients with primary BCS	24
Table (II):	Classification of BCS according to the site of venous obstruction	25
Table (III):	Clinical Presentation of BCS	31
Table (IV):	The schedule of post-intervention follow up	76
Tables of Results		
Table (1):	Age and Gender among the studied groups	80
Table (2):	Results of laboratory investigations to clarify the etiology of BCS among the studied groups:	82
Table (3):	The etiology of BCS in the studied patients:	83
Table (4):	The frequency of single or multiple BCS etiological factors in a single patient in the current study.	85
Table (5):	Clinical presentations of the studied groups (I & II):	87
Table (6):	Assessed laboratory data among the studied groups (I& II).....	88
Table (7):	Child-Pugh score classification of the studied groups	89
Table (8):	Status of liver related veins within studied groups (I & II) assessed by different imaging modalities (Doppler U/S, CT & MRI).....	90

List of Tables

Table No.	Title	Page No.
Table (9):	Status of anticoagulants in the studied groups (I & II).....	91
Table (10):	The type of BCS-related therapeutic options conducted in the studied groups.	92
Table (11):	D-dimer serum levels in the studied groups	93
Table (12):	Description of the site and extent of new thrombosis in Group II.....	95
Table (13):	The Correlation* between D Dimer and other parameters in the studied groups.....	96

List of Figures

Fig. No.	Title	Page No.
Figures of Review of Literature		
Figure (I):	Hepatic blood flow.	6
Figure (II):	Segmental anatomy of the liver	7
Figure (III):	Zones of the liver parenchyma	8
Figure (IV):	Measurements of the portal vein and its main branches, in centimeters.....	10
Figure (V):	Diagram of portal circulation.....	14
Figure (VI):	Histological examination shows sinusoidal dilatation and congestion	26
Figure (VII):	Hepatic venogram showing thrombus in the left hepatic vein	42
Figure (VIII):	Percutaneous angioplasty of segmental stenosis of inferior vena cava.....	42
Figure (IX):	Illustrated diagram for TIPS	43
Figure (X):	Algorithm for management of BCS.....	46
Figure (XI):	The cascade model of fibrin formation	50
Figure (XII):	The cell-based model of fibrin formation	56
Figure (XIII):	Fibrinolytic system.....	60
Figure (XIV):	Degradation of fibrinogen and cross- linked fibrin by plasmin	61
Figure (XV):	Fibrinolysis	62
Figure (XVI):	D-Dimer molecule.....	64

List of Figures (cont...)

Fig. No.	Title	Page No.
Figures of Results		
Figure (1):	Age Distribution in the 2 studied groups.	81
Figure (2):	Sex Distribution in the 2 studied groups as well as the control group.....	81
Figure (3):	Thrombophilia work up among the 2 studied groups.....	83
Figure (4):	The etiology of BCS in the studied patients	84
Figure (5):	Comparison between the 2 studied groups regarding the frequency of etiological factors in a single patient.....	85
Figure (6):	Frequency of single or multiple etiological factors in a single patient.....	86
Figure (7):	Child-Pugh score classification of the studied groups.....	89
Figure (8):	D-dimer serum levels in the studied groups.....	93
Figure (9):	Roc curve for D Dimer as a predictor for new thrombosis in BCS.	94
Figure (10):	The site of new thrombosis in Group II patients	95

List of Abbreviations

Abb.	Meaning
a PTT.....	Activated partial thromboplastin time
ACL.....	Anti cardiolipin
ALB.....	Albumin
ALT.....	Alanin amino-transferase
ANA	Anti Nuclear Antibody
Anti-DNA.....	Anti double stranded DNA
aPC	Activated protein C
APLAS.....	Antiphospholipid antibody syndrome
AST	Aspartate amino-transferase
AT III.....	Anti Thrombin III
BCS.....	Budd-Chiari syndrome
BCSG.....	Budd-Chiari Study Group
BK.....	BradyKinin
BMA.....	Bone marrow aspirate
BUN	Blood Urea Nitrogen
CBC	Complete Blood Count
CD.....	Clusters of differentiation
Cr.	Creatinine
CSF.....	Cerebrospinal fluid
CT	Computed Tomography
CV	Central vein
D. Bil	Direct Bilirubin
Da.....	Dalton (unit)
DIC	Disseminated Intravascular Coagulopathy
DVT	Deep Venous Thrombosis
EASVLD.....	Egyptian Association for the Study of Vascular Liver Diseases
ELFA	Enzyme- linked immunofluorescent immunoassays
ELISA.....	Enzyme-linked immunosorbent assay
ESR.....	Erythrocyte sedimentation rate
Fb.....	Fibrin
FDPs.....	Fibrin Degradation Products
Fg.....	Fibrinogen
FVLM	Factor V Lieden Mutation

List of Abbreviations (cont...)

Abb.	Meaning
GIT :	Gastro-Intestinal Tract
Gla :	Glutamic acid
HA :	Hepatic Artery
Hb :	Hemoglobin
HCC :	Hepato-cellular Carcinoma
HELLP :	Hemolysis, elevated liver enzymes and low platelets
HMWK :	High molecular weight kininogen
HS :	Highly Significant
HSPG :	Heparan sulfated proteoglycans
HV :	Hepatic Vein
IgG :	Immunoglobulin G
IgM :	Immunoglobulin M
INR :	International Normalized Ratio
IV :	Intravenous
IVC :	Inferior Vena Cava
JAK₂ :	Janus tyrosine kinase-2
K :	Kallikrien
K :	Potassium
KFT :	Kidney function test
LAC :	Lupus Anti Coagulant
LL :	Lower Limb
LMWH :	Low Molecular Weight Heparin
MPD :	Myeloproliferative disorders
MPs :	Microparticles
MRI :	Magnetic Resonance Imaging
MTHFR :	Methylenetetrahydro-folate reductase
Na :	Sodium
NS :	Non Significant
PAI :	plasminogen activator inhibitor
PAI-1 :	plasminogen activator inhibitor-1
PC :	Protein C
PE :	Pulmonary Embolism
PGM :	Prothrombin Gene Mutation
PK :	Prekallikrien

List of Abbreviations (cont...)

Abb.	Meaning
Plt.	Platelets
PNH	Paroxysmal nocturnal hemoglobinuria
PPP	Platelet Poor Plasma
PS	Protein S
PT	Prothrombin time
PTFE	Polytetrafluoroethylene
PTT	Partial thromboplastin time
PV	Portal Vein
PVT	Portal Vein Thrombosis
ROC	Receiver operating characteristic
S	Significant
SC	Subcutaneous
SD	Standard Deviation
SPSS	Statistical Package for the Social Sciences
T. Bil	Total Bilirubin
TAFI	thrombin activatable fibrinolysis inhibitor
TF	Tissue Factor
TFPI	Tissue factor pathway inhibitor
TIPS	Transjugular Intrahepatic Portosystemic Shunt
TM	Thrombomodulin
t-PA	Tissue Plasminogen Activator
U/S	Ultrasound
VTE	Venous Thrombo-Embolism
vWF	von Willebrand factor
WBCs	White Blood Cells

INTRODUCTION

Budd-Chiari syndrome (BCS) is a rare disorder defined as hepatic venous outflow obstruction at any level between the hepatic veins and the right atrium but generally implies thrombosis of the hepatic veins and/or the intrahepatic or suprahepatic inferior vena cava (IVC) (*Zahn et al., 2010*).

According to the etiology, BCS can be classified as primary (due to intrinsic intraluminal thrombosis or webs) or secondary (due to intraluminal invasion by a parasite or malignant tumor or extraluminal compression by an abscess, cyst or solid tumor) (*Aydinli and Bayraktar, 2007*).

Thrombosis is the major cause of hepatic vein obstruction. The combination of one or more thrombogenic disorders and a triggering factor is necessary for venous thrombosis, particularly hepatic vein thrombosis. Most patients with BCS have an underlying condition that predisposes to blood clotting. Obstruction is mainly caused by primary intravascular thrombosis. At least one hereditary or acquired hypercoagulable state could be identified in 75% of patients; more than one etiologic factor may play a role in 25% of patients (*Denninger et al., 2000*).

Disorders associated with BCS include the following: hematological disorders including polycythemia rubra vera, paroxysmal nocturnal hemoglobinuria, unspecified myelopro-

liferative disorder, antiphospholipid antibody syndrome, essential thrombocytosis, Inherited thrombotic condition (protein C deficiency, protein S deficiency, antithrombin III deficiency, factor V Leiden mutation), pregnancy, membranous webs, oral contraceptives, chronic infections, chronic inflammatory diseases, tumors, trauma, in addition to the idiopathic cases (*Murad et al., 2009*).

The clinical presentation is highly variable but may be categorized as acute and perhaps fulminant hepatic failure, subacute without evidence of cirrhosis or as chronic with evidence of portal hypertension and cirrhosis (*Zahn et al., 2010*).

Treatment strategy of BCS consists of the following graded approach; (1) anticoagulation, treatment of underlying condition, and symptomatic treatment for complications of portal hypertension in all patients with primary BCS; (2) active search for short-length venous stenoses amenable to angioplasty/stenting; (3) in patients not suited for, or unresponsive to angioplasty/stenting, insertion of a transjugular intrahepatic portosystemic stent shunt (TIPSS) should be considered; (4) and in patients unresponsive to TIPSS, liver transplantation should be considered (*DeLeve et al., 2009*).

Despite the increasing use of TIPSS and the promising results with regard to technical success, the long-term efficacy

of TIPSS is limited by shunt stenosis or occlusion (*Pomier-Layrargues et al., 2012*).

D-dimer is a fibrin degradation product, present as a small protein fragment in the blood after a blood clot is degraded by fibrinolysis. It is so named because it contains two cross-linked D fragments of the fibrinogen protein (*Adam et al., 2009*).

Quantitative D-dimer assays have a comparably high sensitivity, but a lower specificity, resulting in a more confident exclusion of acute VTE, at the expense of more additional imaging testing (*Legnani et al., 2010*).

The use of a quantitative D-dimer as a first-line test in the evaluation of patients with intermediate or low clinical probability of having PE is recommended. Appropriate use of the quantitative immunoturbidimetric D-dimer assay can have a substantial influence in reducing health care costs and, more important, reducing unnecessary radiation dose during imaging to patients (*Gupta et al., 2009*).

When interpreted in conjunction with clinical risk assessment, measurement of D-dimer predicts risk of recurrence of VTE and a positive D-dimer, as well as a negative result, may influence management decisions regarding duration of anticoagulant therapy (*Baglin et al., 2008*).

AIM OF THE WORK

To assess the level of quantitative D-dimer in patients with BCS having confirmed well established intravascular thrombosis and to identify the possibility of using it as a non invasive method in diagnosis of new thrombotic events (HVs, IVC, PV, DVT, PE or reocclusion of stents).